Analysis of the CΥP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population

被引:107
作者
Tateishi, T
Chida, M
Ariyoshi, N
Mizorogi, Y
Kamataki, T
Kobayashi, S
机构
[1] St Marianna Univ, Sch Med, Dept Pharmacol, Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan
[2] Hokkaido Univ, Grad Sch Pharmaceut Sci, Div Pharmacobiodynam, Lab Drug Metab, Sapporo, Hokkaido 060, Japan
[3] Tokokai Daiichi Hosp, Clin Pharmacol Ctr, Tokyo, Japan
关键词
D O I
10.1016/S0009-9236(99)70077-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To analyze the CYP2D6 allele frequencies in a Japanese population and to evaluate the effects of CYP2D6 variants on in vivo CYP2D6 activity as measured by the dextromethorphan metabolic ratio (MR). Methods: Ninety-eight unrelated, healthy Japanese men were phenotyped with dextromethorphan and genotyped by the polymerase chain reaction amplification method for 7 CYP2D6 alleles. Results:The CYP2D6*1, CYP2D6*10 CYP2D6*2 CYP2D6*5, CYP2D6*4, and CYP2D6*21 allele frequencies in our Japanese subjects were 0.423, 0.408, 0.092, 0.061, 0.020, and 0.010, respectively. Thirty-three subjects (33.7%) were heterozygous for *10/*1, and 18 (18.4%) and 17 (17.3%) subjects were homozygous for *1 and *10 respectively. Subjects who were homozygous for *10 showed the highest dextromethorphan MR among these 3 genotypes. Eighteen subjects (18.3%) were heterozygous for *2 but their dextromethorphan MR values were not greater than the MR values of subjects who were homozygous for *1. One subject was a poor metabolizer phenotypically, and he was homozygous for *5. Conclusions The CYP2D6 allele frequencies in our Japanese subjects differed from those determined in previous studies of white subjects or mainland Chinese subjects. Individuals homozygous for *10 who have relatively low in vivo CYP2D6 activity represent almost 20% of the Japanese population. In addition, we did not identify any subjects with amplified *2 among our 98 Japanese men.
引用
收藏
页码:570 / 575
页数:6
相关论文
共 24 条
[1]   GENETIC-BASIS FOR DIFFERENCES IN DEBRISOQUIN POLYMORPHISM BETWEEN A SPANISH AND OTHER WHITE-POPULATIONS [J].
AGUNDEZ, JAG ;
MARTINEZ, C ;
LEDESMA, MC ;
LADONA, MG ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (04) :412-417
[2]   PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION [J].
AGUNDEZ, JAG ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :265-269
[3]  
Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441
[4]   THE CYTOCHROME-P450 CYP2D6 ALLELIC VARIANT CYP2D6J AND RELATED POLYMORPHISMS IN A EUROPEAN POPULATION [J].
ARMSTRONG, M ;
FAIRBROTHER, K ;
IDLE, JR ;
DALY, AK .
PHARMACOGENETICS, 1994, 4 (02) :73-81
[5]   High performance liquid chromatography determination of dextromethorphan and its metabolites in urine using solid-phase extraction [J].
Bartoletti, RA ;
Belpaire, FM ;
Rosseel, MT .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1996, 14 (8-10) :1281-1286
[6]   GEOGRAPHICAL INTERRACIAL DIFFERENCES IN POLYMORPHIC DRUG OXIDATION - CURRENT STATE OF KNOWLEDGE OF CYTOCHROMES P450 (CYP) 2D6 AND 2C19 [J].
BERTILSSON, L .
CLINICAL PHARMACOKINETICS, 1995, 29 (03) :192-209
[7]   DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION [J].
BROLY, F ;
GAEDIGK, A ;
HEIM, M ;
EICHELBAUM, M ;
MORIKE, K ;
MEYER, UA .
DNA AND CELL BIOLOGY, 1991, 10 (08) :545-558
[8]   GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS [J].
DAHL, ML ;
YUE, QY ;
ROH, HK ;
JOHANSSON, I ;
SAWE, J ;
SJOQVIST, F ;
BERTILSSON, L .
PHARMACOGENETICS, 1995, 5 (03) :159-164
[9]  
DAHL ML, 1995, J PHARMACOL EXP THER, V274, P516
[10]   Nomenclature for human CYP2D6 alleles [J].
Daly, AK ;
Brockmoller, J ;
Broly, F ;
Eichelbaum, M ;
Evans, WE ;
Gonzalez, FJ ;
Huang, JD ;
Idle, JR ;
IngelmanSundberg, M ;
Ishizaki, T ;
JacqzAigrain, E ;
Meyer, UA ;
Nebert, DW ;
Steen, VM ;
Wolf, CR ;
Zanger, UM .
PHARMACOGENETICS, 1996, 6 (03) :193-201